

Keywords: Alzheimer's Diseases; APP/PS1; MnSOD; HIF; P-53; Cu-ZnSOD

Abbreviations: AD: Alzheimer's disease; Mn-SOD: Manganese-Super-Oxido-Dismutase; Cu/Zn-SOD: Cu/Zn-Super-Oxido-Dismutase; HIF: Hypoxia Inducible Factor; P-53: P-53 protein; PPAR- α : Peroxisoma Proliferator-Activated Receptor

Introduction

Alzheimer's disease is a common multifactorial neurodegenerative disorder that occurs with aging. The neuropathological hallmarks of Alzheimer's disease (AD) are amyloid plaques, intra-neuronal tangles, and activation of glial cells [1-3]. Glial swelling and astrogliosis are a characteristic response of astrocytes to inflammation, oxidative stress and trauma, leading to secretion of several potentially toxic products, including inflammatory [4] and oxidative stress mediators [5].

Beta amyloid (A β) deposition can result in brain damage and neurodegeneration, but whether astrocytes activation participates in the A β -induced brain damage, and furthermore, its intervention in inflammation and in oxidative stress in AD is poorly known. Also in vivo studies have been demonstrated the involvement of oxidative stress and inflammation in the induction of Alzheimer phenotypes. We demonstrate here oxidative stress and inflammation changes in APP/PS1 transgenic mice [transgenic mice, APP (amyloid precursor protein) and PS1 (Preseniline 1) protein] compared with wild type mice. We determine by western-blot MnSOD and Cu/ZnSOD, such as pro-oxidant proteins, PPAR- α such as anti-inflammatory protein, p-53 and Sir-2 proteins, in transgenic compared with wild type mice. We previously found that oestradiol or genistein attenuate inflammation and oxidative processes, preventing expression of inflammatory mediators and production of peroxide levels, demonstrating antioxidant and anti-inflammatory effects of oestrogens in neurons and astrocytes in primary culture [6]. Furthermore, these compounds promote PPAR- α activation as a regulator of inflammatory responses and consequently protecting cells from A β deleterious effects [7]. Our results here, demonstrate a decreased expression of Mn-SOD, HIF and

p-53 with increase in Sir-2 and without changes in Cu/Zn-SOD and PPAR- α expression in transgenic compared with wild type mice.

Material and Methods

Materials

Dulbecco's modified Eagle's medium (DMEM) and fetal bovine serum (FBS) were obtained from Gibco (Gibco Invitrogen Corporation, Barcelona, Spain). Western Blot Chemiluminescent Detection System (ECL) was from Amersham (Amersham Biosciences, Barcelona, Spain). Antibodies: monoclonal anti-peroxisome proliferator-activated receptor antibody (anti-PPAR α) (1:250) and monoclonal anti- α -tubulin antibody (1:1000) (Santa Cruz Biotechnology, Madrid, Spain), polyclonal anti-Mn-SOD protein antibody (anti-Mn-SOD) (1:500), polyclonal anti-Cu/Zn-SOD antibody (anti-Cu/Zn-SOD) (1:500), polyclonal anti-HIF protein antibody (anti-HIF) (1:250), monoclonal anti-p-53 antibody (anti-p-53) (Sigma Aldrich, Madrid, Spain). All other reagents are analytical or culture grade purity.

Western blot analysis

Protein extracts from brain cells were mixed with equal volumes of SDS buffer (0.125 M Tris-HCl, pH 6.8, 2% SDS, 0.5% (v/v)

*Corresponding author: Soraya L Valles, Ph.D., Department of Physiology,

Citation: Aguirre-Rueda D, Aldasoro M, Santonja S, Guerra S, Iradi A, et al. ÇG€FHĐÁÚ: [ËUçáæ}çæ}áÁQ} 'æ { {æc[!^ÁT^ääæc[!•ÁÚ! [ã~&^áÁQ)ÁV!æ}•*^}á&Á T&^ÁÇCE]]DÚ•FDÁÉÁÓi [&@^ { ÁÚ@^ •i [|ÁGKÁFGFÉÁá [æFÉÉ I FÍGĐGFÍ I ÉJ Í ÍGEF€€€FGF




Figure 2:

Citation: Aguirre-Rueda D, Aldasoro M, Santonja S, Guerra S, Iradi A, et al.